- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02280317
Dose Finding Safety Study of VAL201 in Cancer Patients (VAL201-001)
A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 1
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
The study will enrol patients with locally advanced or metastatic prostate cancer. The MTD/MAD may also be evaluated in patients with other advanced tumour types for whom no standard effective therapy is available and a rationale for use of VAL201 exists.
The average timeframe is 18-26 weeks per subject and the outcome measured is a composite average for each group.
Inclusion criteria:
- Specific Inclusion Criteria for Patients with Prostate Cancer
- Patients with incurable, locally advanced or metastatic prostate cancer where a policy of intermittent hormone therapy has been decided. Who have specific clinical parameters.
Specific Inclusion Criteria for Patients with Other Advanced Solid Tumours
- Patients with histologically and/or cytologically confirmed advanced solid tumour for whom no standard effective therapy is available and a rationale for use of VAL201 exists.
Patients with incurable, locally advanced or metastatic prostate cancer where a policy of intermittent hormone therapy has been decided. These patients must also have the following:
- Rising PSA on three samples (once non-castrate levels established); each over 2 weeks apart, with the last two values being greater than 2 ng/mL. Higher than and at least 25% over the nadir.
- Absent or very mild prostate cancer-related symptoms.
- No plans for any therapy for prostate cancer in the next two months.
- General Inclusion Criteria for all Patients
- Adult patients defined by age greater than 18 years at time of consent.
- Ability to give written, informed consent prior to any study-specific Screening procedures, with the understanding that the consent may be withdrawn by the patient at any time without prejudice.
- Patient is capable of understanding the protocol requirements, is willing and able to comply with the study protocol procedures, and has signed the informed consent document.
- Evaluable disease, either measurable on imaging, or with informative tumour marker(s) and a set of specific biochemical and haematological parameters relating to the specific cancer.
- Negative human chorionic gonadotropin (hCG) test in women of childbearing potential.
- Sexually active male and female patients of childbearing potential must agree to use an effective method of birth control. Female patients may be surgically sterile.
Laboratory values at Screening:
- Absolute neutrophil count ≥1.5 x 109/L.
- Platelets ≥100 x 109/L.
- Haemoglobin ≥9 g/dL without blood transfusion or colony stimulating factor support.
- Total bilirubin <1.5 times the upper limit of normal (ULN);
- AST (SGOT) ≤2.5 times the ULN;
- ALT (SGPT) ≤2.5 times the ULN; ≤5 x ULN for patients with advanced solid tumours with liver metastases.
- Serum creatinine ≤1.5 x ULN or estimated glomerular filtration rate (GFR) of >50 mL/min based on the Cockcroft-Gault formula.
Exclusion criteria
- Specific Exclusion Criteria for Patients with Prostate Cancer Patients has received an anticancer therapy, including investigational agents, within the precious 6 weeks or 4 weeks.
- Any patients who have undergone prior orchidectomy.
- Specific Exclusion Criteria for Patients with Other Advanced Solid Tumours Pregnant or lactating female patients.
- Documented, symptomatic or uncontrolled brain metastases.
- History of clinically significant cardiac condition, including ischemic cardiac event, myocardial infarction or unstable cardiac disease within 3 months previous to the indication of home therapy.
- Known Human Immunodeficiency Virus positivity.
- Active Hepatitis B or C or other active liver disease (other than malignancy).
- Any active, clinically significant, viral, bacterial, or systemic fungal infection within previous 4 weeks prior to home therapy.
- Any medical history that would jeopardize compliance.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Cohort 1: 0.5 mg/kg
VAL201-001 Sub-cutaneous injection.
0.5 mg/kg
|
VAL201-001 Sub-cutaneous injection.
Altri nomi:
|
Sperimentale: Cohort 2: 1 mg/kg
VAL201-001 Sub-cutaneous injection.
1.0 mg/kg
|
VAL201-001 Sub-cutaneous injection.
Altri nomi:
|
Sperimentale: Cohort 3: 2 mg/kg
VAL201-001 Sub-cutaneous injection.
2.0 mg/kg
|
VAL201-001 Sub-cutaneous injection.
Altri nomi:
|
Sperimentale: Cohort 4: 4 mg/kg
VAL201-001 Sub-cutaneous injection.
4.0 mg/kg
|
VAL201-001 Sub-cutaneous injection.
Altri nomi:
|
Sperimentale: Cohort 5: up to 8 mg/kg
VAL201-001 Sub-cutaneous injection.
8.0 mg/kg; potential to escalate to 16 mg/kg after 3 cycles according to clinician decision Flexibility of dosing enabled under protocol.
|
VAL201-001 Sub-cutaneous injection.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Dose-Limiting Toxicity
Lasso di tempo: The average timeframe is 18-26 weeks per subject
|
The number of Dose-Limiting Toxicity events is used to determine whether a maximum tolerated dose (MTD) is obtained.
|
The average timeframe is 18-26 weeks per subject
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Pharmacokinetics of VAL201. (Cmax)
Lasso di tempo: The average timeframe is 18-26 weeks per subject
|
Assessment of pharmacokinetic variables at multiple time points (5 min, 10 min, 15 min, 30 min, 60 min, 90 min, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours after dosing) and multiple dosing days (Cycle 1 Day 1, Cycle 3 Day 1, Cycle 4 Day 1 and Cycle 6 Day 1) for each patient analysed.
|
The average timeframe is 18-26 weeks per subject
|
Pharmacokinetics of VAL201 (AUC 0-inf)
Lasso di tempo: The average timeframe is 18-26 weeks per subject
|
Assessment of pharmacokinetic variables at multiple time points (5 min, 10 min, 15 min, 30 min, 60 min, 90 min, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours after dosing) and multiple dosing days (Cycle 1 Day 1, Cycle 3 Day 1, Cycle 4 Day 1 and Cycle 6 Day 1) for each patient analysed.
|
The average timeframe is 18-26 weeks per subject
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Patients Who Completed 6 Cycles of Treatment
Lasso di tempo: The average timeframe is 18-26 weeks per subject
|
The number of patients who completed 6 cycles of treatment is compared with the number who withdrew prior to completion of the scheduled 6 cycles
|
The average timeframe is 18-26 weeks per subject
|
Number of Patients Displaying Disease Progression by PCWG2 and/or RECIST Criteria
Lasso di tempo: The average timeframe is 18-26 weeks per subject
|
Assessment of disease response to treatment by PCWG2 and/or RECIST.
Disease progression is defined by RECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; and by PCWG2 criteria that PSA values did not see an increase of 25% or more and absolute increase of 2 ng/mL or more from the nadir.
|
The average timeframe is 18-26 weeks per subject
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- VAL201-001
- 2013-004009-25 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Carcinoma della prostata in stadio III
-
Arbeitsgemeinschaft medikamentoese TumortherapieReclutamentoCancro ai polmoni | NSCLC Stadio IV | NSCLC, stadio III | SCLC, Ampio Stage | SCLC, fase limitataAustria
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RitiratoStadio clinico III Adenocarcinoma esofageo AJCC v8 | Stadio clinico III Carcinoma esofageo a cellule squamose AJCC v8 | Adenocarcinoma esofageo in stadio patologico III AJCC v8 | Carcinoma a cellule squamose dell'esofago in stadio III patologico AJCC v8 | Stadio patologico IIIA Adenocarcinoma... e altre condizioniStati Uniti
-
NRG OncologyNational Cancer Institute (NCI)ReclutamentoStadio clinico III Adenocarcinoma della giunzione gastroesofagea AJCC v8 | Adenocarcinoma della giunzione gastroesofagea non resecabile | Terapia postneoadiuvante Fase III Adenocarcinoma della giunzione gastroesofagea AJCC v8 | Terapia postneoadiuvante Fase IIIA Adenocarcinoma della giunzione... e altre condizioniStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteStadio clinico III Adenocarcinoma della giunzione gastroesofagea AJCC v8 | Stadio clinico IV Adenocarcinoma della giunzione gastroesofagea AJCC v8 | Adenocarcinoma metastatico della giunzione gastroesofagea | Adenocarcinoma della giunzione gastroesofagea non resecabile | Neoplasia maligna... e altre condizioniStati Uniti
-
NRG OncologyNational Cancer Institute (NCI)ReclutamentoStadio clinico III Adenocarcinoma della giunzione gastroesofagea AJCC v8 | Terapia postneoadiuvante Fase III Adenocarcinoma della giunzione gastroesofagea AJCC v8 | Terapia postneoadiuvante Fase IIIA Adenocarcinoma della giunzione gastroesofagea AJCC v8 | Terapia postneoadiuvante Fase IIIB... e altre condizioniStati Uniti
-
Mayo ClinicNational Cancer Institute (NCI)Attivo, non reclutanteCancro al polmone in stadio III AJCC v8 | Cancro polmonare in stadio II AJCC v8 | Cancro al polmone in stadio IIA AJCC v8 | Cancro polmonare in stadio IIB AJCC v8 | Cancro polmonare in stadio IIIA AJCC v8 | Cancro polmonare in stadio IIIB AJCC v8 | Cancro al polmone in stadio I AJCC v8 | Stadio IA1... e altre condizioniStati Uniti
-
City of Hope Medical CenterNational Cancer Institute (NCI)Attivo, non reclutanteCancro alla prostata in stadio IV AJCC v8 | Neoplasia epatobiliare | Cancro a cellule renali in stadio III AJCC v8 | Cancro a cellule renali in stadio IV AJCC v8 | Cancro del corpo uterino in stadio III AJCC v8 | Cancro del corpo uterino in stadio IV AJCC v8 | Stadio IVA Cancro del corpo uterino... e altre condizioniStati Uniti